Top

Published in:

Open Access 01-12-2016 | Rapid communication

Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia

Authors: Zhenyi Jin, Qiang Luo, Shuai Lu, Xinyu Wang, Zifan He, Jing Lai, Shaohua Chen, Lijian Yang, Xiuli Wu, Yangqiu Li

Published in: Journal of Hematology & Oncology | Issue 1/2016

Abstract

Background

Recent data have shown that γδ T cells can act as mediators for immune defense against tumors. Our previous study has demonstrated that persisting clonally expanded TRDV4 T cells might be relatively beneficial for the outcome of patients with T cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation (HSCT). However, little is known about the distribution and clonality of the TRDV repertoire in T cell receptor (TCR) of γδ T cells and their effects on the clinical outcome of patients with acute myeloid leukemia (AML). The aim of this study was to assess whether the oligoclonal expansion of TCR Vδ T cells could be used as an immune biomarker for AML outcome.

Findings

γδ T cells were sorted from the peripheral blood of 30 patients with untreated AML and 12 healthy donors. The complementarity-determining region 3 (CDR3) sizes of eight TCR Vδ subfamily genes (TRDV1 to TRDV8) were analyzed in sorted γδ T cells using RT-PCR and GeneScan. The most frequently expressed TRDV subfamilies in the AML patients were TRDV8 (86.67 %) and TRDV2 (83.33 %), and the frequencies for TRDV1, TRDV3, TRDV4, and TRDV6 were significantly lower than those in healthy individuals. The most frequent clonally expanded TRDV subfamilies in the AML patients included TRDV8 (56.67 %) and TRDV4 (40 %). The clonal expansion frequencies of the TRDV2 and TRDV4 T cells were significantly higher than those in healthy individuals, whereas a significantly lower TRDV1 clonal expansion frequency was observed in those with AML. Moreover, the oligoclones of TRDV4 and TRDV8 were independent protective factors for complete remission. Furthermore, the oligoclonal expansion frequencies of TRDV5 and TRDV6 in patients with relapse were significantly higher than those in non-recurrent cases.

Conclusions

To the best of our knowledge, we characterized for the first time a significant alteration in the distribution and clonality of the TRDV subfamily members in γδ T cells sorted from AML patients. Clonally expanded TRDV4 and TRDV8 T cells might contribute to the immune response directed against AML, while oligoclonal TRDV5 and TRDV6 might occur in patients who undergo relapse. While the function of such γδ T cell clones requires further investigation, TRDV γδ T cell clones might be potential immune biomarkers for AML outcome.

Available only for authorised users

Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. New Engl J Med. 2015;373(12):1136–52.CrossRefPubMed

Lu S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol. 2014;7:2.CrossRefPubMedPubMedCentral

Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014;7:74.CrossRefPubMedPubMedCentral

Cheng HH, Soleau C, Yu EY. Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy. J Hematol Oncol. 2015;8:51.CrossRefPubMedPubMedCentral

Chen S, Zha X, Shi L, Zhou L, Yang L, Li B, et al. Upregulated TCR zeta improves cytokine secretion in T cells from patients with AML. J Hematol Oncol. 2015;8:72.CrossRefPubMedPubMedCentral

Xu L, Zhang Y, Luo G, Li Y. The roles of stem cell memory T cells in hematological malignancies. J Hematol Oncol. 2015;8:113.CrossRefPubMedPubMedCentral

Vantourout P, Hayday A. Six-of-the-best: unique contributions of gamma delta T cells to immunology. Nat Rev Immunol. 2013;13(2):88–100.CrossRefPubMedPubMedCentral

Paul S, Lal G. Regulatory and effector functions of gamma-delta (gamma delta) T cells and their therapeutic potential in adoptive cellular therapy for cancer. Int J Cancer. 2016;139(5):976–85.CrossRefPubMed

Saito A, Narita M, Watanabe N, Tochiki N, Satoh N, Yano T, et al. Anti-tumor cytotoxicity of gamma delta T cells expanded from blood cells of myeloma and leukemia patients against self tumor cells—enhancement of the anti-tumor cytotoxicity by type IIFN, dendritic cells, and activated alpha beta T cells. Blood. 2007;110(11):264b.

10.

Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, et al. Plasticity of gamma delta T cells: impact on the anti-tumor response. Front Immunol. 2014;5:662.CrossRef

11.

Braza MS, Klein B. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. Br J Haematol. 2013;160(2):123–32.CrossRefPubMed

12.

Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, et al. Effector gamma delta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia. 2005;19(4):664–70.PubMed

13.

Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol. 2007;139(2):206–16.CrossRefPubMed

14.

D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol. 2010;184(6):3260–8.CrossRefPubMed

15.

Kiladjian JJ, Visentin G, Vieyl E, Chevret S, Eclache V, Stirnemann J, et al. Activation of cytotoxic T-cell receptor gamma delta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematol-Hematol J. 2008;93(3):381–9.CrossRef

16.

Groh V, Porcelli S, Fabbi M, Lanier LL, Picker LJ, Anderson T, et al. Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med. 1989;169(4):1277–94.CrossRefPubMed

17.

Born WK, Aydintug MK, O'Brien RL. Diversity of gamma delta T-cell antigens. Cell Mol Immunol. 2013;10(1):13–20.CrossRefPubMed

18.

Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, et al. Tumor-infiltrating gamma delta T lymphocytes predict clinical outcome in human breast cancer. J Immunol. 2012;189(10):5029–36.CrossRefPubMedPubMedCentral

19.

Xu L, Weng J, Huang X, Zeng C, Chen S, Geng S, et al. Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI. Oncotarget. 2016;7(28):42943–52.PubMed

20.

Zhang X, Chen S, Yang L, Li B, Zhu K, Li Y. The feature of TRGV and TRDV repertoire distribution and clonality in patients with immune thrombocytopenic purpura. Hematology. 2009;14(4):237–44.CrossRefPubMed

21.

Xuan L, Wu X, Zhang Y, Fan Z, Ling Y, Huang F, et al. Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease. J Transl Med. 2011;9(1):1.CrossRef

22.

Geng S, Weng J, Du X, Lai P, Huang X, Chen S, et al. Comparison of the distribution and clonal expansion features of the T-cell gamma delta repertoire in myelodysplastic syndrome-RAEB and RAEB with progression to AML. DNA Cell Biol. 2012;31(10):1563–70.CrossRefPubMed

23.

Wang L, Xu M, Wang C, Zhu L, Hu J, Chen SH, et al. The feature of distribution and clonality of TCR gamma/delta subfamilies T cells in patients with B-cell non-Hodgkin lymphoma. J Immunol Res. 2014;2014:241246.PubMedPubMedCentral

24.

Bartkowiak J, Kulczycka-Wojdala D, Blonski JZ, Robak T. Molecular diversity of gamma delta T cells in peripheral blood from patients with B-cell chronic lymphocytic leukaemia. Neoplasma. 2002;49(2):86–90.PubMed

25.

Yang Q, Li P, Li Y, Wu X, Huang X, Chen Y, et al. Effects of immunotherapy on the distribution and clonality of TCR V gamma and V delta subfamily T cells in allergic rhinitis patients. J Med Biochem. 2012;31(2):94–9.CrossRef

26.

Meeh PF, King M, O’Brien RL, Muga S, Buckhalts P, Neuberg R, et al. Characterization of the γδ T cell response to acute leukemia. Cancer Immunol Immunother. 2006;55(9):1072–80.CrossRefPubMed

27.

Siegers GM, Felizardo TC, Mathieson AM, Kosaka Y, Wang XH, Medin JA, et al. Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph + leukemia model. Plos ONE. 2011;6(2):e16700.CrossRefPubMedPubMedCentral

28.

Zarin P, Chen ELY, In TSH, Anderson MK, Zuniga-Pflucker JC. Gamma delta T-cell differentiation and effector function programming, TCR signal strength, when and how much? Cell Immunol. 2015;296(1):70–5.CrossRefPubMed

29.

Chen S, Huang X, Zheng H, Geng S, Wu X, Yang L, et al. The evolution of malignant and reactive gamma delta plus T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation. Mol Cancer. 2013;12(1):1.CrossRef

30.

Li Y, Geng S, Du X, Chen S, Yang L, Wu X, et al. Restricted TRBV repertoire in CD4(+) and CD8(+) T-cell subsets from CML patients. Hematology. 2011;16(1):43–9.CrossRefPubMed

31.

Li B, Li Y, Chen S, Yang L, Yu W, Chen J, et al. The T-cell receptor V beta gene repertoire and clonal expansion from peripheral blood T cells in benzene-exposed workers in China. Hematology. 2009;14(2):106–10.CrossRefPubMed

32.

Jin Z, Wu X, Chen S, Yang L, Liu Q, Li Y. Distribution and clonality of the V alpha and V beta T-cell receptor repertoire of regulatory T cells in leukemia patients with and without graft versus host disease. DNA Cell Biol. 2014;33(3):182–8.CrossRefPubMedPubMedCentral

33.

Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol. 1994;153(6):2807–18.PubMed

34.

Li Y, Chen S, Yang L, Yin Q, Geng S, Wu X, et al. TRAV and TRBV repertoire, clonality and the proliferative history of umbilical cord blood T-cells. Transpl Immunol. 2007;18(2):151–8.CrossRefPubMed

35.

Li Y, Chen S, Yang L, Li B, Chan J, Cai D. TRGV and TRDV repertoire distribution and clonality of T cells from umbilical cord blood. Transpl Immunol. 2009;20(3):155–62.CrossRefPubMed

Title: Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia
Authors: Zhenyi Jin
Qiang Luo
Shuai Lu
Xinyu Wang
Zifan He
Jing Lai
Shaohua Chen
Lijian Yang
Xiuli Wu
Yangqiu Li
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2016
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-016-0353-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Findings

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

Journal of Hematology & Oncology reviewer acknowledgement 2015

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Second- and third-generation ALK inhibitors for non-small cell lung cancer

A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer